TIMP2 and acute kidney injury: [TIMP-2]∙[IGFBP7] was validated in the Sapphire Study, in which the authors highlighted its remarkable ability to predict the development of moderate and severe AKI (stage 2 to 3) within 12 hours of sample collection12.